...
首页> 外文期刊>Journal of Biomolecular Structure and Dynamics >Computational investigation of binding mechanism of substituted pyrazinones targeting corticotropin releasing factor-1 receptor deliberated for anti-depressant drug design
【24h】

Computational investigation of binding mechanism of substituted pyrazinones targeting corticotropin releasing factor-1 receptor deliberated for anti-depressant drug design

机译:靶向吡嗪释放因子-1受体靶向取代吡嗪酮结合机理的计算研究临床抗抑郁药物设计

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In spite of various research investigations towards anti-depressant drug discovery program, no one drug has not yet launched last 20 years. Corticotropin-releasing factor-1 (CRF-1) is one of the most validated targets for the development of antagonists against depression, anxiety and post-traumatic stress disorders. Various research studies suggest that pyrazinone based CRF-1 receptor antagonists were found to be highly potent and efficacious. In this research investigation, we identified the pharmacophore and binding pattern through 2D and 3D-QSAR and molecular docking respectively. Molecular dynamics studies were also performed to explore the binding pattern recognition. We establish the relationship between activity and pharmacophoric features to design new potent compounds. The best 2D-QSAR model was generated through multiple linear regression method with r2 value of 0.97 and q2 value of 0.89. Also 3D-QSAR model was obtained through k-nearest neighbor molecular field analysis method with q2 value of 0.52 and q2_ se value of 0.36. Molecular docking and binding energy were also evaluated to define binding patterns and pharmacophoric groups, including (i) hydrogen bond with residue Asp284, Glu305 and (ii) p-p stacking with residue Trp9. Compound 11i has the highest binding affinity compared to reference compounds, so this compound could be a potent drug for stress related disorders. Most of the compounds, including reference compounds were found within acceptable range of physicochemical parameters. These observations could be provided the leads for the design and optimization of novel CRF-1 receptor antagonists.
机译:尽管对抗抑郁药物发现计划进行了各种研究调查,但在过去20年中没有任何一种药物尚未推出。 Corticotropin-释放因子-1(CRF-1)是对抑郁,焦虑和创伤后应激障碍发育的最验证的靶标的目标之一。各种研究研究表明,基于吡嗪酮的CRF-1受体拮抗剂是高度有效和有效的。在本研究调查中,我们将药物团和3D-QSAR分别鉴定了药物和结合图案和分子对接。还进行了分子动力学研究以探索结合模式识别。我们建立了活动与药物功能的关系,以设计新的高效化合物。通过多个线性回归方法生成最佳的2D-QSAR模型,R2值为0.97和Q2值为0.89。通过Q2值0.52和Q2_ SE值为0.36的Q2值获得3D-QSAR模型。还评估了分子对接和结合能量以限定结合图案和药物基团,包括(i)与残留物ASP284,GLU305和(II)P-P与残余​​物TRP9堆叠的氢键。与参考化合物相比,化合物11i具有最高的结合亲和力,因此该化合物可以是用于应激相关疾病的有效药物。在可接受的物理化学参数范围内发现大多数化合物,包括参考化合物。可以提供这些观察结果,用于设计和优化新型CRF-1受体拮抗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号